Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Danish biotech Nuevolution completes SEK250mm IPO

Executive Summary

Nuevolution AS (small-molecule drug screening) completed an initial public offering in Sweden and Denmark of 14.2mm shares (including the overallotment) at SEK 17.50, resulting in gross proceeds of SEK250mm ($29.7mm), up-sized from the original SEK225mm amount. The company has applied to trade its shares on Nasdaq's First North Premier exchange, which does not have the same legal status as a regulated marketplace. The offering could potentially be the largest on this exchange so far this year.
Deal Industry
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies